SummaryThe COVID-19 pandemic limits pricing policy options for vaccines. It is therefore necessary to consider what appropriate policy options governments can use to ensure affordable and equitable access to these novel products. Commonly used policies such as fostering competition, generic substitution, and external and internal reference pricing will not work for novel vaccines.

In 2000, the Millennium Development Goals set targets for social achievements by 2015 including goals related to maternal and child health, with mixed success. Several initiatives supported these goals including assuring availability of appropriate medicines and commodities to meet health service targets. We compiled indicator data on 15 commodities related to reproductive, maternal, newborn, and child health (RMNCH) and analyzed them across 75 Countdown to 2015 countries from eight regions to identify problems with specific commodities and determinants of access. The determinants related to policy, regulatory environment, financing, pharmaceutical procurement and supply chain, and information systems. We also developed a dashboard for policy and systems indicators for select countries. The commodities we identified as having the fewest barriers to access had been in use longer. No country reported recent stock-outs of all the 15 commodities at the central level—countries always had some of the 15 commodities available. This analysis highlights country deficiencies in policies and systems, such as incoherent policy guidelines, problems in product registration, lack of logistics data, and central-level stock-outs that may affect access to essential RMNCH commodities.

Subscribe to RSS - access